Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Particle Size on PK of AZD7594 in Healthy Males
NCT02928354Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of velsecorat in asthma and chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at 240 hours, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at 240 hours and 1 more. Started Nov 2016; status: completed.
02
Drugs
velsecorat
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02928354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928354.